Semaglutide + MOTS-C + 5-Amino-1MQ (5mg + 10mg + 50mg)

The combination works via three complementary pathways: **Semaglutide** activates GLP-1 receptors in the hypothalamus, centrally reducing appetite and slowing gastric emptying — result: fewer calories in. **MOTS-C** activates AMPK, the central regulator of energy homeostasis, increasing fatty acid β-oxidation and mitochondrial biogenesis — result: more calories out. **5-Amino-1MQ** inhibits NNMT, increasing intracellular NAD+ and SAM in adipocytes, pushing them towards lipolysis instead of storage — result: conversion of white fat into energy. Together, they reduce intake, increase expenditure, and enhance lipolysis.

• Semaglutide: 0.25–2.4mg SC, 1x/week (slow titration)
• MOTS-C: 5mg SC, 2–3x/week
• 5-Amino-1MQ: 50–100mg PO, 1x/day
• Cycle: 12–16 weeks

1. Semaglutide (5mg): Add 2ml of bacteriostatic water to the vial (concentration 2.5mg/ml). Aim for the side of the vial, do not spray directly. Gently swirl.
2. MOTS-C (10mg): Add 2ml of bacteriostatic water (concentration 5mg/ml = 5000mcg/ml). 5mg = 1.0ml (100 units on an insulin syringe).
3. 5-Amino-1MQ: Administered in capsules — no reconstitution required.

• This stack combines three complementary mechanisms for weight loss:
• Semaglutide — A GLP-1 agonist that acts centrally in the hypothalamus to reduce appetite by 30–40%. It slows gastric emptying, increases satiety, and improves glycemic control. Clinically proven weight loss of ~15% over 68 weeks (STEP trials).
• MOTS-C — A mitochondrial peptide that activates AMPK, the body's 'master metabolic switch'. It increases fatty acid β-oxidation, improves insulin sensitivity, and enhances mitochondrial biogenesis. It metabolically mimics the benefits of exercise.
• 5-Amino-1MQ — An inhibitor of NNMT (Nicotinamide N-methyltransferase), an enzyme that regulates metabolic homeostasis. Inhibiting NNMT increases NAD+ levels in adipocytes, enhances lipolysis, and reduces lipogenesis without affecting food intake.
• The combination targets: central appetite reduction (Semaglutide), mitochondrial metabolic enhancement (MOTS-C), and lipolytic action at the cellular level (5-Amino-1MQ).

• Wks. 1–4 — Introduction: Semaglutide 0.25mg/wk to minimize GI side effects. MOTS-C 5mg 3x/wk. 5-Amino-1MQ 50mg/day.
• Wks. 5–8 — Titration: Increase Semaglutide to 0.5mg/wk. MOTS-C 5mg 3x/wk. 5-Amino-1MQ 100mg/day.
• Wks. 9–12 — Full Dose: Semaglutide 1.0mg/wk. Maintain MOTS-C & 5-Amino-1MQ doses.
• Wks. 13–16 — Maximum (optional): Semaglutide 1.7–2.4mg/wk if tolerated.
• Weigh yourself weekly (same time, morning, fasted). Target: 0.5–1kg/week.
• If significant nausea from Semaglutide occurs, do not increase the dose — remain at the current level for 2 more weeks.
• Break between cycles: After the cycle (12–16 weeks), a washout period of 8–12 weeks is recommended. Semaglutide has a long half-life (~7 days), and its effects are partially maintained. The washout period allows for evaluation of the new weight set point, consolidation of dietary changes, and prevention of metabolic adaptation. Continue exercise and a high-protein diet during the washout phase.

• Semaglutide: Lyophilized powder at 2–8°C. After reconstitution: 2–8°C, use within 28 days.
• MOTS-C: Lyophilized powder at -20°C long-term or 2–8°C short-term. After reconstitution: 2–8°C, use within 21 days.
• 5-Amino-1MQ: Room temperature, away from light and moisture.

• Research stack — there are no clinical studies on this specific triple combination.
• Semaglutide can cause significant GI side effects — slow titration is critical.
• Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (Semaglutide).
• Contraindicated in cases of pancreatitis or severe gastroparesis.
• 5-Amino-1MQ is a recent molecule with limited human safety data.
• Monitor blood glucose, especially if taking other anti-diabetic medications.
• Medical supervision is required throughout the cycle.

1. STEP 1 Trial — Semaglutide 2.4mg — Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
   View Source
2. SELECT Trial — Cardiovascular Outcomes — Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
   View Source
3. STEP 5 Trial — Long-term Semaglutide — Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity. Nat Med. 2022;28(10):2083-2091.
   View Source
4. MOTS-C & AMPK Activation — Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
   View Source
5. MOTS-C & Exercise Mimetic — Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
   View Source
6. MOTS-C Insulin Sensitivity — Kim SJ, et al. MOTS-c: an equal opportunity insulin sensitizer. J Mol Med. 2023;101:487-497.
   View Source
7. 5-Amino-1MQ & NNMT Inhibition — Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of NNMT cause direct, rapid induction of thermogenesis. J Biochem. 2018;163(6):445-455.
   View Source
8. NNMT & Adipose Metabolism — Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262.
   View Source
9. 5-Amino-1MQ Anti-Obesity Effects — Neelakantan H, et al. Structure-activity relationship for small molecule inhibitors of NNMT. J Med Chem. 2017;60(12):5015-5024.
   View Source
10. GLP-1 Receptor Agonists — Mechanism Review — Drucker DJ. Mechanisms of action and therapeutic application of GLP-1 receptor agonists. Cell Metab. 2018;27(4):740-756.
    View Source